Subscribe
clu
clu / iStockphoto.com
12 September 2017Americas

BMS and Pfizer reach settlement with Teva

Bristol-Myers Squibb (BMS) and Pfizer have settled their dispute with Teva over an Abbreviated New Drug Application (ANDA).

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
BMS, Pfizer win patent dispute over blockbuster drug, Eliquis
6 September 2021   In a victory for Bristol-Myers Squibb and Pfizer, the US Court of Appeals for the Federal Circuit has affirmed the validity of a pair of patents covering blood clot treatment, Eliquis.
Americas
BMS sues Mylan to block Reyataz generic
20 March 2015   Bristol-Myers Squibb has sued generic drug maker Mylan for allegedly infringing a patent covering its HIV drug Reyataz.
Americas
Actavis and Pfizer settle Celebrex litigation
29 April 2014   Actavis has entered into an agreement with Pfizer to settle all outstanding patent litigation related to Pfizer’s arthritis drug Celebrex (celecoxib).


Editor's picks

‘We created law’: G1/24 and the creation of the ‘diamond standard’
Europe
‘We created law’: G1/24 and the creation of the ‘diamond standard’
3 July 2025

Editor's picks

Europe
‘We created law’: G1/24 and the creation of the ‘diamond standard’
3 July 2025
Americas
A step too far? Why Stewart’s approach is dividing opinion
24 June 2025
Europe
Diverging in the detail: UPC local divisions and Court of Appeal take different paths
19 June 2025
Europe
UPC confirms permanent injunction against Curio in 10x tech dispute
17 June 2025
Americas
LSPN: In-house ‘chess game’ is the same, but the rules have changed
9 May 2025
Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025

More on this story

Americas
BMS, Pfizer win patent dispute over blockbuster drug, Eliquis
6 September 2021   In a victory for Bristol-Myers Squibb and Pfizer, the US Court of Appeals for the Federal Circuit has affirmed the validity of a pair of patents covering blood clot treatment, Eliquis.
Americas
BMS sues Mylan to block Reyataz generic
20 March 2015   Bristol-Myers Squibb has sued generic drug maker Mylan for allegedly infringing a patent covering its HIV drug Reyataz.
Americas
Actavis and Pfizer settle Celebrex litigation
29 April 2014   Actavis has entered into an agreement with Pfizer to settle all outstanding patent litigation related to Pfizer’s arthritis drug Celebrex (celecoxib).

More on this story

Americas
BMS, Pfizer win patent dispute over blockbuster drug, Eliquis
6 September 2021   In a victory for Bristol-Myers Squibb and Pfizer, the US Court of Appeals for the Federal Circuit has affirmed the validity of a pair of patents covering blood clot treatment, Eliquis.
Americas
BMS sues Mylan to block Reyataz generic
20 March 2015   Bristol-Myers Squibb has sued generic drug maker Mylan for allegedly infringing a patent covering its HIV drug Reyataz.
Americas
Actavis and Pfizer settle Celebrex litigation
29 April 2014   Actavis has entered into an agreement with Pfizer to settle all outstanding patent litigation related to Pfizer’s arthritis drug Celebrex (celecoxib).

More features

‘We created law’: G1/24 and the creation of the ‘diamond standard’
BMS unit loses cell therapy patent at European Patent Office
Amgen sues Biocon over blockbuster bone drugs as first biosimilars enter market
Lord Justice Birss to become chancellor of the High Court
Bankruptcy judge approves $305m sale of genetics testing company
Sanofi successfully challenges rare disease patent in Europe
Bayer appoints new head of IP
WATCH: Policy direction—where are we now?